Global Healthcare Sector Sees 14 Deals: Internet Prophet Mary Meeker Spotlights Digital Inflection Point in Health
VCBeat News
2017-06-05
VCBeat interviewed four deans of internet hospitals, including Li Tiantian of DXY Yinchuan Internet Hospital, Ma Ding of Xingren Internet Hospital, Pang Chenglin, General Manager and Executive Dean of 39 Internet Hospital, and Zeng Mingfa, founder of Kangkang Chronic Disease Internet Hospital, aiming to address questions regarding the management of internet hospitals.
2017-06-06
Early Screening and Diagnosis of Lung Cancer Through the Development of New Technologies: Providing New Possibilities for Early Detection, Early Treatment, and Reduced Missed Diagnoses. Market observations indicate that new technologies such as artificial intelligence and liquid biopsy have already made progress in the early detection and treatment of lung cancer. To this end, VCBeat (WeChat ID: vcbeat) has compiled a list of companies involved in the research and development of related technologies and products in the field of lung cancer, offering insights into the current landscape both in China and abroad.
2017-06-07
In just the first five months of 2017, capital market investments in the oncology liquid biopsy sector exceeded $1.3 billion. We screened 109 liquid biopsy companies from China and the United States from the VCBeat database, comprising 71 Chinese companies and 38 U.S. companies. We compiled and analyzed their financing data (from 2015 to the present) to identify differences between China and the United States and gain insights into future trends.
2017-06-08
In the 1990s, Mary Meeker became a figure whom practitioners approached with trepidation while studying her Internet Trends Report, thanks to her precise predictions of emerging trends in the internet industry. Many took pride in having their sectors “handpicked” by Meeker. Today, the “Queen of the Internet” opens with the bold and direct assertion that “healthcare has reached a digital inflection point,” expressing strong confidence in the future development of the healthcare industry.
2017-06-09
In just the first five months of 2017, capital market investments in the oncology liquid biopsy sector exceeded $1.3 billion. We screened 109 liquid biopsy companies from China and the United States from the VCBeat database, comprising 71 Chinese companies and 38 U.S. companies. We compiled and analyzed their financing data (from 2015 to the present) to identify differences between China and the United States and gain insights into future trends.
VCBeat Viewpoint
How Can Aesthetic Medicine Clinics Achieve a 1:10 Return on Investment in Online Marketing?
CEO of So-YoungVenus
The Matthew Effect on the internet is highly pronounced. For medical aesthetic institutions, it is better to be a big fish in a small pond than a small fish in a large pond; in other words, they must strive to become leaders within a specific category. The approach to achieving this is straightforward: by combining various elements such as target demographics, pricing, categories, procedures, geographic regions, and even design, service, packaging, and business models, institutions can identify their unique advantages, select niche markets, and establish differentiated positioning. For instance, on the SoYoung platform, a hospital in Dalian specializes exclusively in a popular Korean-style upturned nose procedure, enjoying tremendous business success.
Pricing in the medical aesthetics industry is also a topic worthy of in-depth discussion. The demand-price curve adheres to fundamental business realities: for the same product, as price increases, demand correspondingly decreases. High-quality content and guided shopping experiences can make the demand-price curve slightly flatter; however, it is important to note that this does not fundamentally alter the curve itself. Rather, its primary effect lies in enabling marketing efforts to reach a broader audience and expand the user base.
Big Data Will Enable Precise Decision-Making in Healthcare
Dean, Peking University Health Science Center Jian Qimin
Health big data is not merely a simple process of collection; it embodies scientific thinking and necessitates research into the standards governing data generation, as well as data analysis, ethics, and security. More importantly, scientific research represented by big data must be closely integrated with community health needs. This integration serves as the primary source of big data: starting from clinical and community issues or needs, conducting translational research to generate scientific outcomes, and then feeding these back into clinical and community health services through new interventions and management measures, or via novel molecular markers and early diagnostic methods.
The past development model was largely sustained by environmental pollution and resource depletion. As this approach is unsustainable, China has been actively seeking new models of economic growth. Strategic research has identified the health economy as a new highlight in China’s economic development. Currently, the health economy contributes approximately 7% to China’s GDP, whereas developed countries generally exceed 12%, with the United States reaching 24%. Therefore, there remains significant potential for the health economy to drive China’s overall development.
Struggling to Implement Family Doctor Contracting? The Method Is Wrong
CEO of Community 580 Liu Bo
Family Doctors Are Not a New Term. Pilot programs for family doctor contract services have been implemented in certain regions of China for several years, yet they have received public acclaim without achieving substantial uptake. First, residents’ healthcare-seeking habits are not easily changed in the short term, and it will take time to effectively implement the family doctor model. Second, there is a significant shortage of general practitioners in China, particularly experienced senior general practitioners, making “signed but not serviced” a widespread phenomenon.
The "Notice on Issuing the Guiding Opinions on Promoting Family Doctor Contracted Services," issued by the state in June 2016, provided policy support for the family doctor contracted service model, elevated family doctor services to a national strategy, and set forth specific implementation targets. It required that the coverage rate of family doctor contracted services reach over 30% by 2017.
Capital Dynamics
This week, in the medical field both domestically and internationally, there are a total of14Financing event.
Policy Updates
National Health and Family Planning Commission Launches DRG Payment Reform Pilot; C-DRG to Become New Standard for Hospital Billing and Payment!
On June 2, the National Health and Family Planning Commission held a launch meeting in Shenzhen, Guangdong Province, for the pilot program on reforming payment systems based on Diagnosis-Related Groups (DRGs). At the meeting, Wang Peian, Deputy Director of the National Health and Family Planning Commission, emphasized that the DRG-based payment reform pilot is one of the key tasks of this year’s healthcare reform. Provinces where pilot cities are located must provide strong support to these pilot areas and actively encourage other eligible regions and medical institutions to carry out pilot work in accordance with national requirements.
Six Departments Issue the “13th Five-Year” Special Plan for Scientific and Technological Innovation in Health and Healthcare
Recently, the Ministry of Science and Technology, the National Health and Family Planning Commission, the General Administration of Sport of China, the China Food and Drug Administration, the State Administration of Traditional Chinese Medicine, and the Logistics Support Department of the Central Military Commission jointly issued the “13th Five-Year” Special Plan for Scientific and Technological Innovation in Health. The document outlines twelve key tasks, including strengthening applied basic research, promoting frontier technological innovation, enhancing disease prevention and control capabilities, safeguarding the health of priority populations, developing pharmaceutical and health products, advancing new health service technologies, strengthening control of health risk factors, promoting scientific and technological popularization, advancing the modernization of traditional Chinese medicine, strengthening the construction of innovation bases and platforms as well as capacity building, facilitating the transfer and commercialization of scientific and technological achievements, and establishing an international cooperation network.
Event Updates
Industry Dynamics
Trending Events
Chinese Consortium Acquires U.S.-Based SciClone Pharmaceuticals for $605 Million
SaiSheng Pharma announced on June 8 that it has accepted a $605 million acquisition offer jointly initiated by five Chinese investment institutions, including CDH Investments, BOC Group Investment Limited, Top Glory Capital, Boying Venture Capital, and Defu Capital. SaiSheng stated that this acquisition not only creates value for the company’s shareholders but also facilitates better business operations in China.
Henan’s Public Hospitals to Eliminate Drug Markups Entirely, Implementation by End of September
The 15% drug markup is finally set to be abolished, making medications more affordable for the public at public hospitals. Reporters learned from the Henan Provincial Development and Reform Commission that the commission recently issued the "Notice on Addressing Issues Related to the Reform of Medical Service Prices in Urban Public Hospitals" (hereinafter referred to as the "Notice"), requiring all public hospitals at every level and of every type to completely eliminate drug markups by the end of September. The revenue shortfall resulting from the removal of drug markups will be offset through adjustments to medical service prices.
Health 160 Helps Shenzhen People's Hospital Launch WeChat Pay
Recently, Shenzhen People’s Hospital partnered with Health 160 to upgrade its in-hospital payment and refund systems. Patients can quickly make payments by scanning the QR code located in the upper-left corner of their prescription slips via WeChat. Scanning the same QR code again allows patients to review their payment status. Currently, scan-to-pay services at Shenzhen People’s Hospital cover all prescription slips and laboratory test orders, as well as selected imaging orders such as ultrasound and radiology examinations. However, scan-to-pay is not yet available for examination orders that require departmental pricing.
Listed Company
Jiangsu Yuwell
On the evening of June 6, Yunnan Baiyao issued an announcement stating that its controlling shareholder, Baiyao Holdings, plans to introduce Jiangsu Yuwell Technology Development Co., Ltd. (hereinafter referred to as “Jiangsu Yuwell”) as a third-party shareholder through a capital increase. Under this capital increase, Jiangsu Yuwell intends to inject approximately RMB 5.638 billion into Baiyao Holdings in exchange for a 10% equity stake. Based on this transaction, Baiyao Holdings’ valuation in this capital increase is estimated at RMB 56.38 billion. This represents a slight increase compared to the valuation of approximately RMB 50.74 billion during the capital injection by New Huadu Industrial.
Fosun Pharma
On June 6, Fosun Pharma and Fosun International issued a joint announcement stating that Fosun Pharma and its controlling shareholder, Fosun International, had jointly applied to the Hong Kong Stock Exchange (HKEX) in accordance with the Listing Rules for approval of the proposed spin-off and separate listing of Sisram, a non-wholly owned subsidiary of Fosun Pharma, on the Main Board of The Stock Exchange of Hong Kong Limited. The HKEX has confirmed that Fosun Pharma and Fosun International may proceed with the proposed spin-off and listing.
Jiuzhitang
On June 9, Jiuzhitang announced that it plans to use its own funds of RMB 199 million to increase capital in Beijing Kexin Meide Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Kexin Meide”), subscribing for a 5.87% equity stake. Of this amount, RMB 12.9536 million will be allocated to the newly added registered capital, and the remaining RMB 186 million will be recorded as capital reserve.
Jinshi Oriental
On the evening of June 7, Jinshi Oriental announced its acquisition of Hainan Yiyao, stating that Jinshi Oriental and its wholly-owned subsidiary, Chengdu Jinshi, collectively hold 86.5938% of the equity in Hainan Yiyao.
Dashenlin
On June 6, the Main Board Issuance Review Committee of the China Securities Regulatory Commission (CSRC) approved Dashenlin’s initial public offering (IPO) application. Dashenlin plans to issue no fewer than 40 million shares, raising RMB 1.8 billion.
Frontiers of Technology
In-Depth Report
Detailed weekly report content is available in the VCBeat knowledge base!
